抗瘤增效方结合化疗治疗中晚期非小细胞肺癌97例

Combination of “Kangliu Zengxiao Formula”and chemotherapy for the treatment of advanced non-small cell lung cancer: report of 97 cases

目的观察抗瘤增效方结合化疗治疗中晚期非小细胞肺癌的临床疗效和安全性。方法采用随机对照前瞻性研究方法,将195例精气两亏型非小细胞肺癌住院患者分为治疗组(97例)和对照组(98例)。两组均采用诺维本+顺铂方案化疗,治疗组加服抗瘤增效方。两组均以4周为1个周期,连续治疗4个周期;观察实体瘤客观疗效以及生存质量、血清肿瘤标志物变化情况,监测毒副作用和不良反应,并随访生存情况。结果①治疗组、对照组疾病控制率分别为89.69%、69.39%;组间实体瘤客观疗效比较,差异有统计学意义(P<0.05)。治疗组、对照组生存质量总有效率分别为93.81%、59.18%;组间生存质量疗效比较,差异有统计学意义(P<0.05)。②治疗后治疗组VEGF下降(P<0.05),对照组VEGF升高(P<0.05);组间治疗后比较,VEGF差异有统计学意义(P<0.05)。③与对照组比较,治疗组中位生存期延长(P<0.05),1年、2年生存率显著提高(P<0.05)。④组间比较,恶心、呕吐、便秘及WBC下降情况差异有统计学意义(P<0.01)。结论抗瘤增效方可有效提高中晚期非小细胞肺癌化疗的近期疗效,延长患者的生存时间,明显改善患者的生存质量,降低化疗药物的毒副作用。

Objective To observe the clinical efficacy and safety of ＂Kangliu Zengxiao Formula＂ and chemotherapy in treating advanced non-small cell lung cancer （NSCLC）. Methods One hundred and ninety-five cases with NSCLC of deficiency of essence and qi pattern were randomized into treatment group （ n = 97 ） and control group （ n = 98 ） by randomized prospective study. Both of the groups were treated with navebine （ NVB ） and cisplatin, dichloro diamine platinum （cis-DDP）, and treatment group was treated with ＂Kangliu Zengxiao Formula＂ additionally. Four weeks as one course, with the course of 4 weeks continuously. The solid tumor＇s effect, quality of life, changes of tumor markers, side effects and adverse effects were observed, and follow-up the survival condition. Results （1） The disease control rate was 89.69% in the treatment group and 69.39% in the control group. There was a significant difference in objective curative effect in solid tumor between the two groups （ P 〈 0.05 ）. The total effective rate of QOL was 93.81% in the treatment group and 59.18% in the control group, with a significant difference between the two groups （P 〈 0.05）. （2） After treatment, the VEGF was decreased in treatment gnop, but increased in control group, with significant difference between the two groups （ P 〈 0. 05 ）. （3） Compared with control group, the median survival time was prolonged in treatment group （ P 〈 0. 05 ） , and the 1 -year survival rate and 2-year survival rate were increased markedly （ P 〈 0. 05 ）. （4） There were significant differences in nausea, vomiting, constipation and reduction of WBC between the two groups （ P 〈 0.01 ）. Conclusion ＂Kangliu Zengxiao Formula＂ can improve the short-term effect, prolong the survival time, improve the quality of life, reduce the side effects in NSCLC patients with the treatment of chemotherapy.